The principal objecfive of the Biostatistics Core will be to provide project investigators a centralized resource for statistical expertise. Statisfical issues will be addressed at all levels of investigation: from the design o experiments to the conclusions drawn from them, and from the maintenance of data quality to the modeling fo human studies and trials. In support of this objective, the specific aims ofthe Biostatistics Core include: 1. To collaborate with project investigators in the formulation of hypotheses and hypothesis testing strategies, and in the design of experiments. Phase I trials, and population studies. 2. To conduct the statistical analyses of data generated by project invesfigators including: descriptive summary statistics, data modeling, hypothesis tesfing, and methods of discovery. 3. To ensure that the following statistical principles are adhered to in all studies: modeling nuisance or block effects, controlling Type I error to produce reliable conclusions, using adequate sample sizes to control Type II error and avoid inconsistent conclusions, using randomization of conditions to avoid systematic errors, and decreasing measurement error to enhance precision. 4. To provide design expertise and oversight for the Phase I Trials and support the design of possible future Phase II trials. 5. To collaborate with the bioinformatics core for all microarray analyses. 6. To investigate or develop new statistical methodologies to direcfiy address difficult data or design problems. 7. To provide design and data analyfic support from senior biostafisficians for the new investigators responsible for the pilot projects.
The SPORE requires a variety of statistical support, from modeling population longitudinal data to hypothesis testing strategies for mulfiple measures in donor cell experiments. Expertise in experimental and trial design, statistical genetics, multiplicity problems, microarray analyses, and mixed modeling, and familiarity with CLL and AML were the requirements used for designing the pool of expertise found in this Biostafisfics Core.
|Mims, Alice S; Mishra, Anjali; Orwick, Shelley et al. (2018) A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485. Haematologica 103:982-987|
|Walker, Christopher J; Oakes, Christopher C; Genutis, Luke K et al. (2018) Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA. Leukemia :|
|Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia 32:1338-1348|
|Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia 32:2536-2545|
|Miller, Cecelia R; Ruppert, Amy S; Heerema, Nyla A et al. (2017) Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. Blood Adv 1:1584-1588|
|Tsai, Yo-Ting; Lakshmanan, Aparna; Lehman, Amy et al. (2017) BRAFV600E accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemia. Blood Adv 1:2147-2160|
|Eisfeld, A-K; Mrózek, K; Kohlschmidt, J et al. (2017) The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia. Leukemia 31:2211-2218|
|Papaioannou, Dimitrios; Shen, Changxian; Nicolet, Deedra et al. (2017) Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia. Proc Natl Acad Sci U S A 114:E4641-E4647|
|Woyach, Jennifer A; Ruppert, Amy S; Guinn, Daphne et al. (2017) BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. J Clin Oncol 35:1437-1443|
|Blum, W; Sanford, B L; Klisovic, R et al. (2017) Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503). Leukemia 31:34-39|
Showing the most recent 10 out of 229 publications